{{one source|date=August 2014}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 409083557
| IUPAC_name = 7-(3-Aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
| image = tosufloxacin.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|tosufloxacin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 100490-36-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 5517
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = GHJ553KQPS
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02317
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 77573
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 273348
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 5316


<!--Chemical data-->
| C=19 | H=15 | F=3 | N=4 | O=3 
| molecular_weight = 404.34 g/mol
| smiles = NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI =1S/C19H15F3N4O3/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = WUWFMDMBOJLQIV-UHFFFAOYSA-N
}}

'''Tosufloxacin''' is a [[fluoroquinolone]] [[antibiotic]]. It has a controversial safety profile in relation to other fluoroquinolones. It is associated with severe thrombocytopenia and nephritis, and hepatotoxicity.<ref>{{Cite journal | last1 = Rubinstein | first1 = E. | title = History of quinolones and their side effects. | journal = Chemotherapy | volume = 47 Suppl 3 | issue =  | pages = 3–8; discussion 44–8 | month =  | year = 2001 | doi =  10.1159/000057838| pmid = 11549783 }}</ref> It is sold in [[Japan]] under the brand name '''Ozex'''.

==See also==
* [[Quinolones]]

==References==
{{reflist}}

{{QuinoloneAntiBiotics}}

[[Category:Fluoroquinolone antibiotics]]
[[Category:Naphthyridines]]
[[Category:Pyrrolidines]]
[[Category:Carboxylic acids]]


{{antibiotic-stub}}